Compass Therapeutics (NASDAQ:CMPX) Cut to Hold at Lifesci Capital

Compass Therapeutics (NASDAQ:CMPX) was downgraded by investment analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Several other brokerages have also commented on CMPX. Wedbush set a $4.00 price target on shares of Compass Therapeutics in a research note on Wednesday. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a report on Wednesday. Piper Sandler lifted their target price on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. Finally, Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $10.21.

Compass Therapeutics Stock Down 5.6%

Shares of CMPX opened at $1.17 on Tuesday. The stock has a 50 day moving average price of $2.12 and a 200 day moving average price of $2.93. The company has a market capitalization of $210.71 million, a price-to-earnings ratio of -2.92 and a beta of 0.95. Compass Therapeutics has a 52-week low of $1.13 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities analysts anticipate that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CMPX. Welch & Forbes LLC raised its stake in Compass Therapeutics by 26.7% during the 4th quarter. Welch & Forbes LLC now owns 19,000 shares of the company’s stock valued at $102,000 after acquiring an additional 4,000 shares during the last quarter. Parallel Advisors LLC acquired a new stake in Compass Therapeutics during the 1st quarter worth approximately $28,000. ProShare Advisors LLC grew its stake in shares of Compass Therapeutics by 41.0% in the 4th quarter. ProShare Advisors LLC now owns 23,972 shares of the company’s stock valued at $129,000 after purchasing an additional 6,968 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Compass Therapeutics by 2,572.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company’s stock valued at $58,000 after purchasing an additional 10,625 shares during the last quarter. Finally, HB Wealth Management LLC acquired a new position in shares of Compass Therapeutics in the second quarter valued at approximately $29,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics News Summary

Here are the key news stories impacting Compass Therapeutics this week:

• Positive Sentiment: Citizens JMP maintained a Market Outperform rating but lowered its price target to $4.00. The target implies substantial potential upside if Compass successfully addresses regulatory concerns and advances tovecimig toward approval.
• Positive Sentiment: Compass said it intends to continue pursuing the program despite the FDA feedback, signaling that management believes tovecimig remains commercially viable and that the additional regulatory requirements can be addressed. Compass vows to press on with FDA application despite new trial request
• Neutral Sentiment: Analysts and commentary described tovecimig as having a promising opportunity in biliary tract cancer, but warned that the development and regulatory window is becoming narrower, increasing execution risk. Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
• Negative Sentiment: The FDA recommended that Compass conduct a trial demonstrating a survival benefit in previously treated, advanced biliary tract cancer before submitting a Biologics License Application. This could materially delay a potential filing, raise development costs and require additional financing. Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
• Negative Sentiment: Wedbush downgraded CMPX from Outperform to Neutral and cut its price target to $1 from $5, citing the FDA’s additional-trial request and estimating further downside. LifeSci Capital also downgraded the stock to Hold. Wedbush Downgrades Compass Therapeutics

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients.

Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells.